What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
As many of us struggle with multi-drug
Read Article
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
UCB has issued a press update on its pending application for the approval of their
The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.
Read Article
Links:
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
Read Article
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
Read Article
Editor's Note: please note the error in the original report has been corrected to read: UCB affirms there are no open information requests from the FDA regarding the BLA for bimekizumab or bimekizumab manufacturing.
UCB, the maker of the IL-17 A/F inhibitor
Read Article
Links:
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Read Article
Links:
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
Read Article
Links:
Links:
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023
Read Article
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care. A recent analysis of Norway registry data answers this
Read Article
Links:
The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read Article
Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271
Links:
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
29 pts w/ PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/
Links:
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read Article
